Unimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans

By Brian Finan, Tao Ma, Nickki Ottaway, T. Müller, K. Habegger, K. Heppner, H. Kirchner, J. Holland, Jazzminn Hembree, C. Raver and 23 more. Science Translational Medicine, 2013

636 citations recorded by the source corpus.

Subfields: Endocrine and Autonomic Systems, Endocrinology, Diabetes and Metabolism, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/b1359d450492bc38667bad0dc4f9204fa973f4a7

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrine and Autonomic Systems

In Endocrinology, Diabetes and Metabolism

In Molecular Biology

Citations in the corpus

Hypothalamic circuits regulating appetite and energy homeostasis: pathways to obesity (2017, background): “…(GIP) receptor, another important metabolic hormone in glucose homeostasis (GIPR/GLP-1R), exhibit higher efficacy in terms of body weight reduction and glycemic control while giving rise to fewer side effects compared with equimolar doses of mono-agonists in rodents and humans (Finan et al., 2013).”
Glucagon-like peptide 1 (GLP-1) (2019, background): “Several studies in mice [465,467,685,774] and humans [783e787] have failed to detect changes in energy expenditure following chronic or acute peripheral treatment with different GLP-1R agonists.”
Update on the treatment of type 2 diabetes mellitus. (2016, result): “Finan et al [342] showed that an acylated version of GLP1 and GIP dual agonist, reduced weight (-18.8% vs -8.8%, P 0.001), food intake ( P 0.05), fat mass ( P 0.001) and blood glucose ( P 0.05), compared to liraglutide.”
Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. (2018, background): “An acylated co-agonist that recognizes both the GLP-1 and GIP receptors produced greater metabolic benefits (glucose control and weight loss) in preclinical studies (including acute studies in non-human primates) relative to GLP-1R agonism alone (Finan et al., 2013).”
LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept (2018, background): “In support of this, studies in DIO mice showed the body weight lowering effects of GLP-1RA are enhanced upon coadministration of a long-acting GIP analogue [31].”